A back translation of pregabalin and carbamazepine against evoked and non-evoked endpoints in the rat spared nerve injury model of neuropathic pain

Neuropharmacology

Volumn 73, Issue , 2013, Pages 204-215

  Lau, W ^a   Dykstra, C ^a   Thevarkunnel, S ^a   Silenieks, L B ^a   De Lannoy, I A M ^a   Lee, D K H ^a   Higgins, G A ^a,b  

^a InterVivo Solutions Inc   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Efficacy; Exposure; Pharmacokinetic; Translation

Indexed keywords

CARBAMAZEPINE; PREGABALIN;

ALLODYNIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR DISORDER; BODY POSTURE; BRAIN PROTECTION; COLD SENSITIVITY; CONTROLLED STUDY; CORE TEMPERATURE; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; EVOKED SOMATOSENSORY RESPONSE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NEUROPATHIC PAIN; NONHUMAN; OPEN FIELD TEST; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; REFLEX; SCIATIC NERVE INJURY; SPARED NERVE INJURY; TACTILE STIMULATION; THERMAL STIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TONIC SEIZURE; TOXICITY TESTING; WALKING;

EFFICACY; EXPOSURE; PHARMACOKINETIC; TRANSLATION;

ANIMALS; BEHAVIOR, ANIMAL; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GAIT; GAMMA-AMINOBUTYRIC ACID; HYPERALGESIA; MALE; MOTOR ACTIVITY; NEURALGIA; PERIPHERAL NERVE INJURIES; PHYSICAL STIMULATION; POSTURAL BALANCE; RATS; ROTAROD PERFORMANCE TEST;

EID: 84885122260     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.05.023     Document Type: Article

References (57)

1. Andrews, N., Legg, E., Lisak, D., Issop, Y., Richardson, D., Harper, S., Pheby, T., Huang, W., Burgess, G., Machin, I., Rice, A.S., 2012. Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain. Eur. J. Pain 16, 485-495.
2. Angeby-Möller, K., Berge, O.G., Hamers, F.P., 2008. Using the CatWalk method to assess weight-bearing and pain behaviour in walking rats with ankle joint monoarthritis induced by carrageenan: effects of morphine and rofecoxib. J. Neurosci. Methods 174, 1-9.
3. Attal, N., Jazat, F., Kayser, V., Guilbaud, G., 1990. Further evidence for 'pain-related' behaviours in a model of unilateral peripheral mononeuropathy. Pain 41, 235-251.
4. Bauer, CS., Nieto-Rostro, M., Rahman, W., Tran-Van-Minh, A., Ferron, L, Douglas, L., Kadurin, I., Sri Ranjan, Y., Fernandez-Alacid, L, Millar, N.S., Dickenson, A.H., Lujan, R., Dolphin, A.C., 2009. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J. Neurosci. 29, 4076-4088.
5. Ben-Menachem, E., 2004. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45 (Suppl. 6), 13-18.
6. Berge, O.G., 2011. Predictive validity of behavioural animal models for chronic pain. Br. J. Pharmacol. 164, 1195-1206.
7. Berry, D., Millington, C, 2005. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Ther. Drug Monit. 27, 451-456.
8. Bian, F., Li, Z., Offord, J., Davis, M.D., McCormick, J., Taylor, C.P., Walker, LC, 2006. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res. 1075, 68-80.
9. Blackburn-Munro, G., 2004. Pain-like behaviours in animals - how human are they? Trends Pharmacol. Sci. 25, 299-305.
10. Brodie, M.J., 2004. Pregabalin as adjunctive therapy for partial seizures. Epilepsia 45 (Suppl. 6), 19-27.
11. Cui, J.G., Holmin, S., Mathiesen, T., Meyerson, B.A., Linderoth, B., 2000. Possible role of inflammatory mediators in tactile hypersensitivity in rat models of mononeuropathy. Pain 88, 239-248.
12. de Medinaceli, L., Freed, W.J., Wyatt, R.J., 1982. An index of the functional condition of rat sciatic nerve based on measurements made from walking tracks. Exp. Neurol. 77, 634-643.
13. De Vry, J., Kuhl, E., Franken-Kunkel, P., Eckel, G., 2004. Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur. J. Pharmacol. 491, 137-148.
14. Deacon, R.M., 2006. Burrowing in rodents: a sensitive method for detecting behavioral dysfunction. Nat. Protoc. 1, 118-121.
15. Deacon, R.M., 2009. Burrowing: a sensitive behavioural assay, tested in five species of laboratory rodents. Behav. Brain Res. 200, 128-133.
16. Decosterd, I., Woolf, C.J., 2000. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87, 149-158.
17. Decosterd, I., Allchorne, A., Woolf, C.J., 2004. Differential analgesic sensitivity of two distinct neuropathic pain models. Anesth. Analg. 99, 457-463.
18. 2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol. Sci. 28, 75-82.
19. Dowdall, T., Robinson, I., Meert, T.F., 2005. Comparison of five different rat models of peripheral nerve injury. Pharmacol. Biochem. Behav. 80, 93-108.
20. Dworkin, R.H., Corbin, A.E., Young Jr, J.P., Sharma, U., LaMoreaux, L., Bockbrader, H., Garofalo, E.A., Poole, R.M., 2003. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60, 1274-1283.
21. Dworkin, R.H., O'Connor, A.B., Audette, J., Baron, R., Gourlay, G.K., Haanpää, M.L., Kent, J.L., Krane, E.J., Lebel, A.A., Levy, R.M., Mackey, S.C., Mayer, J., Miaskowski, C., Raja, S.N., Rice, A.S., Schmader, K.E., Stacey, B., Stanos, S., Treede, R.D., Turk, D.C., Walco, G.A., Wells, C.D., 2010. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc. 85 (3 Suppl.), S3-S14.
22. Eisenberg, E., River, Y., Shifrin, A., Krivoy, N., 2007. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 67, 1265-1289.
23. Erichsen, H.K., Blackburn-Munro, G., 2002. Pharmacological characterisation of the spared nerve injury model of neuropathic pain. Pain 98, 151-161.
24. Field, M.J., Bramwell, S., Hughes, J., Singh, L., 1999. Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones? Pain 83, 303-311.
25. Field, M.J., Cox, P.J., Stott, E., Melrose, H., Offord, J., Su, T.Z., Bramwell, S., Corradini, L., England, S., Winks, J., Kinloch, R.A., Hendrich, J., Dolphin, A.C., Webb, T., Williams, D., 2006. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl. Acad. Sci. U. S. A. 103, 17537-17542.
26. Finnerup, N.B., Sindrup, S.H., Jensen, T.S., 2010. The evidence for pharmacological treatment of neuropathic pain. Pain 150, 573-581.
27. Fox, A., Gentry, C., Patel, S., Kesingland, A., Bevan, S., 2003. Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. Pain 105, 355-362.
28. Gabrielsson, J., Green, A.R., Van der Graaf, P.H., 2010. Optimising in vivo pharmacology studies - practical PKPD considerations. J. Pharmacol. Toxicol. Methods 61, 146-156.
29. Gustafsson, H., Sandin, J., 2009. Oral pregabalin reverses cold allodynia in two distinct models of peripheral neuropathic pain. Eur. J. Pharmacol. 605, 103-108.
30. Hu, P., Bembrick, A.L., Keay, K.A., McLachlan, E.M., 2007. Immune cell involvement in dorsal root ganglia and spinal cord after chronic constriction or transection of the rat sciatic nerve. Brain Behav. Immun. 21, 599-616.
31. Hunter, J.C., Gogas, K.R., Hedley, L.R., Jacobson, L.O., Kassotakis, L., Thompson, J., Fontana, D.J., 1997. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur. J. Pharmacol. 324, 153-160.
32. Idanpaan-Heikkila, J.J., Guilbaud, G., 1999. Pharmacological studies on a rat model of trigeminal neuropathic pain: baclofen, but not carbamazepine, morphine or tricyclic antidepressants, attenuates the allodynia-like behaviour. Pain 79, 281-290.
33. Kilkenny, C., Browne, W., Cuthill, I.C., Emerson, M., Altman, D.G., NC3Rs Reporting Guidelines Working Group, 2010. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br. J. Pharmacol. 160, 1577-1579.
34. Klapdor, K., Dulfer, B.G., Hammann, A., Van der Staay, F.J., 1997. A low-cost method to analyse footprint patterns. J. Neurosci. Methods 75, 49-54.
35. Kontinen, V.S., Meert, T.F., 2003. Predictive validity of neuropathic pain models in pharmacological studies with a behavioural outcome in the rat: a systematic review in book. In: Dostrovsky, J.O., Carr, D.B., Koltzenburgal, M. (Eds.), Proc. of the 10th World Congress on Pain. IASP Press, Seattle, WA, pp. 489-498.
36. Li, C.Y., Song, Y.H., Higuera, E.S., Luo, Z.D., 2004. Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J. Neurosci. 24, 8494-8499.
37. Li, Z., Taylor, C.P., Weber, M., Piechan, J., Prior, F., Bian, F., Cui, M., Hoffman, D., Donevan, S., 2011. Pregabalin is a potent and selective ligand for a(2)d-1 and a(2)d-2 calcium channel subunits. Eur. J. Pharmacol. 667, 80-90.
38. Luo, Z.D., Calcutt, N.A., Higuera, E.S., Valder, C.R., Song, Y.H., Svensson, C.I., Myers, R.R., 2002. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J. Pharmacol. Exp. Ther. 303, 1199-1205.
39. Melrose, H.L., Kinloch, R.A., Cox, P.J., Field, M.J., Collins, D., Williams, D., 2007. [3H] Pregabalin binding is increased in ipsilateral dorsal horn following chronic constriction injury. Neurosci. Lett. 417, 187-192.
40. Mogil, J.S., 2009. Animal models of pain: progress and challenges. Nat. Rev. Neurosci. 10, 283-294.
41. Mogil, J.S., Davis, K.D., Derbyshire, S.W., 2010a. The necessity of animal models in pain research. Pain 151, 12-17.
42. Mogil, J.S., Graham, A.C., Ritchie, J., Hughes, S.F., Austin, J.S., Schorscher-Petcu, A., Langford, D.J., Bennett, G.J., 2010b. Hypolocomotion, asymmetrically directed behaviors (licking, lifting, flinching, and shaking) and dynamic weight bearing (gait) changes are not measures of neuropathic pain in mice. Mol. Pain 6, 34.
43. Morgan, M.M., Christie, M.J., 2011. Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br. J. Pharmacol. 164, 1322-1334.
44. Munro, G., Storm, A., Hansen, M.K., Dyhr, H., Marcher, L., Erichsen, H.K., Sheykhzade, M., 2012. The combined predictive capacity of rat models of algogen-induced and neuropathic hypersensitivity to clinically used analgesics varies with nociceptive endpoint and consideration of locomotor function. Pharmacol. Biochem. Behav. 101, 465-478.
45. Na, H.S., Yoona, Y.W., Chung, J.M., 1996. Both motor and sensory abnormalities contribute to changes in foot posture in an experimental rat neuropathic model. Pain 67, 173-178.
46. Nakazato-Imasato, E., Tanimoto-Mori, S., Kurebayashi, Y., 2009. Effect of mexiletine on dynamic allodynia induced by chronic constriction injury of the sciatic nerve in rats. J. Vet. Med. Sci. 71, 991-994.
47. Nightingale, S., 2012. The neuropathic pain market. Nat. Rev. Drug Discov. 11, 101-102.
48. Piesla, M.J., Leventhal, L., Strassle, B.W., Harrison, J.E., Cummons, T.A., Lu, P., Whiteside, G.T., 2009. Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. Brain Res. 1295, 89-98.
49. Qu, L., Ma, C., 2011. Animal models of pain after peripheral nerve injury. In: Ma, C., Zhang, J.-M. (Eds.), Animal Models of Pain, Neuromethods, Vol. 49, pp. 69-80.
50. Rice, A.S., Cimino-Brown, D., Eisenach, J.C., Kontinen, V.K., Lacroix-Fralish, M.L., Machin, I., Preclinical Pain Consortium, Mogil, J.S., Stöhr, T., 2008. Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain 139, 243-247.
51. Rode, F., Thomsen, M., Broløs, T., Jensen, D.G., Blackburn-Munro, G., Bjerrum, O.J., 2007. The importance of genetic background on pain behaviours and pharmacological sensitivity in the rat spared serve injury model of peripheral neuropathic pain. Eur. J. Pharmacol. 564, 103-111.
52. Tanimoto-Mori, S., Nakazato-Imasato, E., Toide, K., Kita, Y., 2008. Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries. Behav. Pharmacol. 19, 85-90.
53. Taylor, C.P., 2009. Mechanisms of analgesia by gabapentin and pregabalinecalcium channel alpha2-delta [alpha2-delta] ligands. Pain 142, 13-16.
54. Toth, C., 2012. Drug safety evaluation of pregabalin. Expert Opin. Drug Saf. 11, 487-502.
55. Varejão, A.S., Cabrita, A.M., Geuna, S., Melo-Pinto, P., Filipe, V.M., Gramsbergen, A., Meek, M.F., 2003. Toe out angle: a functional index for the evaluation of sciatic nerve recovery in the rat model. Exp. Neurol. 183, 695-699.
56. Vartanian, M.G., Radulovic, L.L., Kinsora, J.J., Serpa, K.A., Vergnes, M., Bertram, E., Taylor, C.P., 2006. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 68, 189-205.
57. Whiteside, G.T., Adedoyin, A., Leventhal, L., 2008. Predictive validity of animal pain models? A comparison of the pharmacokineticepharmacodynamic relationship for pain drugs in rats and humans. Neuropharmacology 54, 767-775.